Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Face Masks Considerably Reduce Covid-19 Cases in Germany

View ORCID ProfileTimo Mitze, Reinhold Kosfeld, View ORCID ProfileJohannes Rode, View ORCID ProfileKlaus Wälde
doi: https://doi.org/10.1101/2020.06.21.20128181
Timo Mitze
aDepartment of Business and Economics, University of Southern Denmark, Campusvej 66, 5230 Odense, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timo Mitze
Reinhold Kosfeld
bUniversität Kassel, Institute of Economics, Nora-Platiel-Str. 4, 34127 Kassel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Rode
cDepartment of Law and Economics, Technische Universität Darmstadt, Hochschulstraße 1, 64289 Darmstadt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johannes Rode
Klaus Wälde
dGutenberg School of Management and Economics, Johannes-Gutenberg-Universität Mainz, Jakob-Welder-Weg 4, D-55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Klaus Wälde
  • For correspondence: waelde{at}uni-mainz.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We use the synthetic control method to analyze the effect of face masks on the spread of Covid-19 in Germany. Our identification approach exploits regional variation in the point in time when face masks became compulsory. Depending on the region we analyse, we find that face masks reduced the cumulative number of registered Covid-19 cases between 2.3% and 13% over a period of 10 days after they became compulsory. Assessing the credibility of the various estimates, we conclude that face masks reduce the daily growth rate of reported infections by around 40%.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was used to support this research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No trials took place on any individual nor was private data gathered on any individual. Data was collected strictly at the country level.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • tmitze{at}sam.sdu.dk, rkosfeld{at}uni-kassel.de, rode{at}vwl.tu-darmstadt.de

Data Availability

We use the official German statistics on reported Covid-19 cases from the Robert Koch Institute (RKI, 2020). The RKI collects the data from local health authorities and provides updates on a daily basis. Using these data (available via API), we build a balanced panel for 401 NUTS Level 3 regions and 95 days spanning the period from January 28 to May 1, 2020 (38,095 observations). We use the cumulative number of registered Covid-19 cases in each district as main outcome variable. We estimate overall effects for this variable together with disaggregated effects by age groups (persons aged 15-34 years, 35-59 years and 60+ years). As an alternative outcome variable, we also use the cumulative incidence rate. Table 1 shows summary statistics for both variables for our sample period.

https://npgeo-corona-npgeo-de.hub.arcgis.com/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Face Masks Considerably Reduce Covid-19 Cases in Germany
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Face Masks Considerably Reduce Covid-19 Cases in Germany
Timo Mitze, Reinhold Kosfeld, Johannes Rode, Klaus Wälde
medRxiv 2020.06.21.20128181; doi: https://doi.org/10.1101/2020.06.21.20128181
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Face Masks Considerably Reduce Covid-19 Cases in Germany
Timo Mitze, Reinhold Kosfeld, Johannes Rode, Klaus Wälde
medRxiv 2020.06.21.20128181; doi: https://doi.org/10.1101/2020.06.21.20128181

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)